HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer

NCT07232875 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

588

Enrollment

INDUSTRY

Sponsor class

Conditions

KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting

Interventions

DRUG: HRS-4642 + AG
DRUG: HRS-4642 placebo + AG

Sponsor

Jiangsu HengRui Medicine Co., Ltd.